A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
NCT07109700 on ClinicalTrials.gov · last registry update 2025-08-17
Recruiting now, toward 216 participants. Its estimated completion date, 31 January 2026, has passed with no update to the record. Primary outcome, as filed: Change from baseline in Hemoglobin A1c (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- dulaglutideTrulicity
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 216
- Started
- 2025-04-30
- Primary completion
- 2026-01-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in Hemoglobin A1c (HbA1c)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.